Beo Therapeutics ApS: Financial statements 2022
CVR: 39880377
Source: annual report 2022, Danish Business Authority
01/01/2022 – 31/12/2022
Beo Therapeutics ApS (CVR 39880377) has filed annual accounts for 2022. In 2022, the company reported a net result of DKK 0 compared with DKK 418 the year before. Equity in the 2022 report amounted to DKK 40,000. The solvency ratio was 100%.
- Profit/Loss
- DKK 0
- Equity
- DKK 40,000
- Total Assets
- DKK 40,000
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2022 | - | - | 0 | 40 t. | - |
| 2021 | - | - | 418 | 40 t. | - |
| 2020 | - | - | 0 | 67 t. | - |
Official annual report
Keep an eye on Beo Therapeutics ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
Beo Therapeutics ApS has published its annual report for 2021. The net result was DKK 418.
About Beo Therapeutics ApS
Beo Therapeutics ApS is a Danish company of the type Anpartsselskab based in København N, founded in 2018. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named Beo Therapeutics IVS. The management consists of Rikke Christina Nielsen. The company is owned by Rikke Christina Nielsen. The company has 1 employee (2026). In 2025, the company reported a gross profit of DKK 0 and a net result of DKK 4,985 compared with DKK -4,910 the year before. Equity in the 2025 report amounted to DKK 40,075.